|Ms. Adelene Q. Perkins||Chairman & CEO||1.15M||N/A||1960|
|Dr. Stephane Peluso Ph.D.||Chief Scientific Officer||577.63k||N/A||1970|
|Dr. Robert Ilaria Jr., M.D.||Chief Medical Officer||643.54k||N/A||1961|
|Dr. Lawrence E. Bloch J.D., M.D.||Pres & Treasurer||N/A||N/A||1966|
|Ms. Melissa Hackel||VP of Fin.||N/A||N/A||N/A|
|Dr. Jeffery L. Kutok M.D., Ph.D.||Chairman of Scientific Advisory Board||N/A||N/A||1967|
|Mr. Seth A. Tasker J.D.||Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.||N/A||N/A||1979|
|Ms. Rossitza Alargova Ph.D.||Head of Pharmaceutical Devel.||N/A||N/A||N/A|
|Jayne Kauffman||Sr. Exec. Coordinator||N/A||N/A||N/A|
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc.’s ISS governance QualityScore as of 31 July 2022 is 5. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 3; Compensation: 6.